Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting.
about
Effect of a monofunctional phenanthriplatin-DNA adduct on RNA polymerase II transcriptional fidelity and translesion synthesisAdvances in drug delivery system for platinum agents based combination therapyStructural and mechanistic studies of polymerase bypass of phenanthriplatin DNA damageCytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivativesTransition Metal Intercalators as Anticancer Agents-Recent AdvancesOxidative Reactivity and Cytotoxic Properties of a Platinum(II) Complex Prepared by Outer-Sphere Amide Bond Coupling.Disturbance of DNA conformation by the binding of testosterone-based platinum drugs via groove-face and intercalative interactions: a molecular dynamics simulation study.Synthesis, Characterization, and Interaction with Biomolecules of Platinum(II) Complexes with Shikimic Acid-Based Ligands.Excellent correlation between drug release and portal size in metalla-cage drug-delivery systems.Probing platinum-adenine-n3 adduct formation with DNA minor-groove binding agentsOsmium(VI) complexes as a new class of potential anti-cancer agents.Effects of monofunctional platinum agents on bacterial growth: a retrospective study.Understanding and improving platinum anticancer drugs--phenanthriplatinRates of intercalator-driven platination of DNA determined by a restriction enzyme cleavage inhibition assay.Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapyPhotoinduced interactions of two dirhodium complexes with d(GTCGAC)2 probed by 2D NOESY.In vitro and in vivo antitumor activities and DNA binding mode of five coordinated cyclometalated organoplatinum(II) complexes containing biphosphine ligands.Sequence-specific recognition of cancer drug-DNA adducts by HMGB1a repair proteinA first-in-class and a fished out anticancer platinum compound: cis-[PtCl2(NH3)2] and cis-[PtI2(NH3)2] compared for their reactivity towards DNA model systems.Modulation of Ligand Fluorescence by the Pt(II)/Pt(IV) Redox Couple.Novel oxidatively activated agents modify DNA and are enhanced by ercc1 silencing.Monofunctional and higher-valent platinum anticancer agents.Synthetic methods for the preparation of platinum anticancer complexes.Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.Targeting and delivery of platinum-based anticancer drugs.Metal complex interactions with DNA.Target-selective delivery and activation of platinum-based anticancer agents.Effect of cisplatin containing liposomes formulated by unsaturated chain-containing lipids on gynecological tumor cells.Investigation of the biological and anti-cancer properties of ellagic acid-encapsulated nano-sized metalla-cages.A dual-targeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complex.Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity.Synthesis and biological studies of pyrazolyl-diamine Pt(II) complexes containing polyaromatic DNA-binding groups.Monofunctional platinum complexes containing a 4-nitrobenzo-2-oxa-1,3-diazole fluorophore: distribution in tumour cells.Oxidatively activated DNA-modifying agents for selective cytotoxicity.The chiral potential of phenanthriplatin and its influence on guanine binding.The effect of sodium thiosulfate on the metabolism of cis-platin in human plasma in vitro.N-acetyl-L-cysteine modulates the metabolism of cis-platin in human plasma in vitro.Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro.Photo-induced DNA cleavage activity and remarkable photocytotoxicity of lanthanide(III) complexes of a polypyridyl ligand.Mono- and Di-Alkylation Processes of DNA Bases by Nitrogen Mustard Mechlorethamine.
P2860
Q24613748-7F7059A8-CA69-4375-9D17-E78F511CD6C9Q26771390-6213EB42-EE62-4F00-99D9-C57C2276E687Q27684330-3A5F8917-8AAF-40CA-8053-90EC09D5147EQ27702884-696B74A9-D813-4A53-A84D-0323BAD03DC8Q28077365-4F96B2C2-3B0F-4C08-BFF8-2DE725029A93Q30443889-7E009DA6-3688-4F02-89DD-02505124464BQ30538107-E9F541A0-FA55-4BFB-8A3A-F7B34B701AB4Q30607784-82F556F8-ABDB-43B5-8299-5732891A3A95Q33953543-4A845E70-90C0-4964-B049-842DF6F2E486Q34092149-B00D8E55-A99F-49A4-980F-30DE0F6BC0B9Q34157363-70AE3AC1-AA08-4184-BD95-A511017F5C0AQ34393918-BF06F8E3-B9C2-40C8-A3A7-A950818C89A9Q34396623-CA43347A-0970-4A8F-ADE6-77BBB656C9C6Q34629768-02DCF0EB-CBBE-4DD7-8B81-522B1C16EC00Q35128594-1F066E64-97EC-453E-97DF-3244ED5F9C93Q35147166-44594E5E-B7FE-40B1-93B8-3E47BABD7E37Q35216231-B5D588F8-B570-4526-8287-0EC8D232E58CQ35962767-9A3A2BC8-3705-41EE-8147-96E5B7D78527Q36002521-E88E7591-3416-4670-9245-59F17BF34480Q36111844-7C48FC89-E2E2-4AD2-8EFF-968AF1B8EB14Q36441829-682733BF-B52C-43C4-85C1-7000045783B7Q37282213-07DD9EA4-D85E-4C8C-B6C0-8BD50F9A6F91Q37722632-67485B39-DD89-4848-8EA2-8C8E0F6CF8A1Q38011996-A9062229-45C9-42AC-ACC9-1ECFFE56D96BQ38050063-BC681AC8-E0F9-4885-8436-FD784EBEBC77Q38271731-28F10620-0233-4E00-A257-6B66DDC43D2FQ38523600-6FC049B6-1205-46A1-8140-28B9A0682433Q38796115-1F07C051-1078-4BBD-9F2F-BB1B05DAA1ACQ38835595-93F8BD78-9C8C-4F61-AED4-2F432CED76DAQ38994934-776A11D3-C367-416A-B866-4A97CB669973Q39235908-AAC7D815-371E-46D9-B1DC-F19779BDA449Q39265471-6AD729FC-3C69-43B9-9D39-0A045070E84EQ39522999-A3624BE2-0DEA-410D-894C-0C8012050C98Q39581383-224E5BB1-0D24-4DF9-B9C7-FF9A1EE52FCEQ41984036-10E82C75-D3A4-4CF1-99C9-86571A34577CQ43529077-1208FB42-56CE-4685-BC3B-5EE6D137E390Q45241480-C2DC34FA-ADA4-45DB-ADC3-A4A52182E3D0Q45795847-8D8B8FC3-97A7-4ADD-8D8A-AF996BDCE349Q45994880-498E79B5-0C50-4A2D-BFD1-25C689AEBA98Q46294125-FEC40517-924A-43A7-ABD6-C81983D9DD42
P2860
Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Non-traditional platinum compo ...... lability, and tumor targeting.
@en
Non-traditional platinum compo ...... lability, and tumor targeting.
@nl
type
label
Non-traditional platinum compo ...... lability, and tumor targeting.
@en
Non-traditional platinum compo ...... lability, and tumor targeting.
@nl
prefLabel
Non-traditional platinum compo ...... lability, and tumor targeting.
@en
Non-traditional platinum compo ...... lability, and tumor targeting.
@nl
P2860
P356
P1433
P1476
Non-traditional platinum compo ...... lability, and tumor targeting.
@en
P2093
Katherine S Lovejoy
Stephen J Lippard
P2860
P304
10651-10659
P356
10.1039/B913896J
P407
P577
2009-10-01T00:00:00Z